Article
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.
Cancer cell - 13 Jan 2020
Kurppa Kari J, Liu Yao, To Ciric, Zhang Tinghu, Fan Mengyang, Vajdi Amir, Knelson Erik H, Xie Yingtian, Lim Klothilda, Cejas Paloma, Portell Andrew, Lizotte Patrick H, Ficarro Scott B, Li Shuai, Chen Ting, Haikala Heidi M, Wang Haiyun, Bahcall Magda, Gao Yang, Shalhout Sophia, Boettcher Steffen, Shin Bo Hee, Thai Tran, Wilkens Margaret K, Tillgren Michelle L, Mushajiang Mierzhati, Xu Man, Choi Jihyun, Bertram Arrien A, Ebert Benjamin L, Beroukhim Rameen, Bandopadhayay Pratiti, Awad Mark M, Gokhale Prafulla C, Kirschmeier Paul T, Marto Jarrod A, Camargo Fernando D, Haq Rizwan, Paweletz Cloud P, Wong Kwok-Kin, Barbie David A, Long Henry W, Gray Nathanael S, Jänne Pasi A
Abstract excerpt
Eradicating tumor dormancy that develops following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment of EGFR-mutant non-small cell lung cancer, is an attractive therapeutic strategy but the mechanisms governing this process are poorly understood. Blockade of ERK1/2 reactivation following EGFR TKI treatment by combined EGFR/MEK inhibition uncovers cells that survive by entering a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.